Tesamorelin reduced belly fat without affecting other fat or weight in HIV patients with abdominal obesity.

Scientific Claim

In HIV-infected patients with abdominal obesity, tesamorelin treatment was associated with a 15% reduction in visceral adipose tissue without changes in subcutaneous adipose tissue or body mass index.

Original Statement

“In two Phase III clinical trials of HIV-infected patients with abdominal obesity, tesamorelin selectively reduced VAT area by 15% over 26 weeks without altering subcutaneous adipose tissue (SAT) or body mass index (BMI).”

From study:Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study design supports association claims. The language appropriately reflects the observed selective reduction without implying causation.

Evidence from Studies

Supporting (1)

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Contradicting (0)

No contradicting evidence found

Source Study

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Score: 62

DOI: 10.1097/QAD.0000000000001614

Similar Assertions

HIV patients with belly fat who took tesamorelin had a 69% chance of losing at least 8% visceral fat, while those on placebo had only a 33% chance, showing a clear benefit from the drug.

97%

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

93%

A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.

93%

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

92%

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

92%